You are here

Regeneron says its antibody drug shows protection against COVID-19 for up to 8 months

Primary tabs

Regeneron says its antibody drug shows protection against COVID-19 for up to 8 months

Mon, 2021-11-08 11:16 — mike kraft

Regeneron's antibody drug shows protection against COVID-19 for up to 8 months The antibody therapy, REGEN-COV, is currently authorized in the United States to treat people with mild-to-moderate COVID-19 and for prevention of infection in those exposed to infected individuals, and others at high risk of exposure in settings such as nursing homes or prisons. The extended authorization could help boost sales of Regeneron's antibody cocktail, in the face of competition from oral COVID-19 pills such as those being developed by Pfizer Inc and Merck & Co. Data showed that Regeneron's drug has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network, making it particularly helpful for immunocompromised people and those unresponsive to vaccines. YahooNews

Country / Region Tags:

General Topic Tags:

Medical Testing

Problem, Solution, SitRep, or ?:

Situation Report

Groups this Group Post belongs to:

Medical - global

- Private group -

Log in or register to post comments

Workflow history

Revision ID	Field name	Date	Old state	New state name	By	Comment	Operations
			No state	No state

Page loaded in 0.451 seconds.